ArticleScience (New York, N.Y.)2012
The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host.
Article in Science (New York, N.Y.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
196 citing papers in PubMed, 1 synthesis or guideline pooled it, 359 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of Practices Exposing Humans to Avian Influenza Viruses, Their Prevalence, and Rationale.The American journal of tropical medicine and hygiene · 2017Pooled it
- AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells.The Journal of infectious diseases · 2019Trial
- Trial
- Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.PloS one · 2016Trial
- A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.Human vaccines & immunotherapeutics · 2014Trial
- Equine influenza virus at 70: What horses taught us about flu.PLoS pathogens · 2026Article
- Filamentous morphology of influenza A virus confers enhanced stability in aerosols.Nature communications · 2026Article
- Unique phenomenon of H5 highly pathogenic avian influenza virus in China: co-circulation of Clade 2.3.4.4b H5N1 and H5N6 results in diversity of H5 Virus.Emerging microbes & infections · 2025Article
- Introducing a framework for within-host dynamics and mutations modelling of H5N1 influenza infection in humans.Journal of the Royal Society, Interface · 2025Article
- Clade 2.3.4.4b highly pathogenic avian influenza H5N1 viruses: knowns, unknowns, and challenges.Journal of virology · 2025Review
- Mutations in the influenza virus, primarily H5N1, enhance the virus's virulence, favor receptor interaction, and increase drug resistance.International journal of surgery (London, England) · 2025Article
- Capacitive Biosensor for Rapid Detection of Avian (H5N1) Influenza andACS sensors · 2025Article
- Pathogenicity of Highly Pathogenic Avian Influenza A/H5Nx Viruses in Avian and Murine Models.Pathogens (Basel, Switzerland) · 2025Article
- Quantifying Time-Dependent Predictors for the International Spatial Spread of Highly Pathogenic Avian Influenza H5NX: Focus on Trade and Surveillance Efforts.Transboundary and emerging diseases · 2025Article
- Genetic evolution and molecular characteristics of avian influenza viruses in Jining from 2018 to 2023.Frontiers in microbiology · 2025Article
- Exploring genetic signatures of zoonotic influenza A virus at the swine-human interface with phylogenetic and ancestral sequence reconstruction.Virus evolution · 2025Article
- Cytomegalovirus vaccine vector-induced effector memory CD4 + T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge.Nature communications · 2024Article
- Biosafety, biosecurity, and bioethics.Monash bioethics review · 2024Review
- Divergent Pathogenesis and Transmission of Highly Pathogenic Avian Influenza A(H5N1) in Swine.Emerging infectious diseases · 2024Article
- Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.Journal of virology · 2024Article
136 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 6 institutions in 5 countries.
Funding
Abstract
Avian A/H5N1 influenza viruses pose a pandemic threat. As few as five amino acid substitutions, or four with reassortment, might be sufficient for mammal-to-mammal transmission through respiratory droplets. From surveillance data, we found that two of these substitutions are common in A/H5N1 viruses, and thus, some viruses might require only three additional substitutions to become transmissible via respiratory droplets between mammals. We used a mathematical model of within-host virus evolution to study factors that could increase and decrease the probability of the remaining substitutions evolving after the virus has infected a mammalian host. These factors, combined with the presence of some of these substitutions in circulating strains, make a virus evolving in nature a potentially serious threat. These results highlight critical areas in which more data are needed for assessing, and potentially averting, this threat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.